Sotrovimab Expanded Access Treatment Protocol (COVID-19)

Vir Biotechnology

Status

Conditions: Covid19

Treatments: Biological: Sotrovimab

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT05235347

VIR-7831-6406

Details and patient eligibility

About

An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• In the opinion of the investigator, meets the current Emergency Use Authorization (EUA) eligibility criteria for sotrovimab

OR

• patients currently hospitalized for a non-COVID-19 illness who acquire COVID-19 (nosocomial infection) and otherwise meets all the current EUA eligibility criteria

Exclusion criteria

• Hospitalized due to COVID-19 (excludes nosocomial infection)
• Require oxygen therapy due to COVID-19, OR who require an increase in baseline oxygen flow rate due to COVID-19